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Abstract
Background: Dogs suffer from spontaneous tumors which may be amenable to therapies developed for human
cancer patients, and dogs may serve as large-animal cancer models. A non-pathogenic Semliki Forest virus vector
VA7-EGFP previously showed promise in targeting human tumor xenografts in mice, but the oncolytic capacity of
the virus in canine cancer cells and the safety of the virus in higher mammals such as dogs, are not known. We
therefore assessed the oncolytic potency of VA7-EGFP against canine cancer cells by infectivity and viability assays
in two dog solid tumor cell lines. Furthermore we performed a 3-week safety study in two adult Beagles which
received a single intravenous injection of ~2 × 105 plaque forming units of parental A7(74) strain.
Results: VA7-EGFP was able to replicate in and kill both canine cancer cell lines tested. No adverse events were
observed in either of the two virus-injected adult Beagles and no infective virus could be recovered from any of the
biological samples collected over the course of the study. Neutralizing antibodies to Semliki Forest virus became
detectable in the dogs at 5 days post infection and remained elevated until study termination.
Conclusions: Based on these results, testing of the oncolytic potential of attenuated Semliki Forest virus in canine
cancer patients appears feasible.
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Background
Canine tumors resemble human malignancies at cellu-
lar, phenotypic, and genomic levels, and dogs may serve
as a more realistic cancer model system since their lar-
ger body size is more amenable to different surgical
techniques and enables better evaluation of biodistribu-
tion of drugs and biotherapeutics than laboratory ro-
dent models [1–3]. Because of the unmet therapeutic
need in treatment of domestic animal neoplasms and
the prospect of using pet cancer patients to narrow the
gap to human clinical translation, the development of
novel biological therapies to address canine malignan-
cies is justifiable. Such therapies include oncolytic
viruses, many of which are capable of infecting also
non-human cells [4, 5]. Oncolytic viruses replicate pref-
erentially in tumor cells and may potentially spread to
distant metastases via the circulation. In addition, virus
infection triggers inflammation which under optimal
circumstances can break tumor immunosuppression
and evoke anti-tumor immune responses [5, 6].
Alphaviruses are enveloped, single-stranded, positive
sense RNA viruses of the family Togaviridae, and some
of them have shown promising oncolytic potential in
preclinical model systems [5, 7]. As animal viruses,
alphaviruses may prove ideal candidates for develop-
ment oncolytic virus therapies for dogs. Moreover,
while most alphavirus strains show neurotropism allow-
ing these viruses to pass the blood–brain-barrier to
infect cells of the central nervous system (CNS), onco-
lytic alphaviruses based on nonvirulent strains remain
apathogenic and are spontaneously cleared by the im-
mune system [8].
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In previous studies, oncolytic alphavirus VA7, which is
based on an attenuated A7(74) strain of Semliki Forest
virus (SFV), was capable of eradicating human brain tu-
mors and melanoma xenografts in immunocompromised
mice following just a single intravenous injection [9, 10],
while in other occasions intratumoral administration
route was proven superior [11–13]. Oncolytic capacity of
attenuated SFV and also other alphaviruses is dependent on
the lack of type I interferon responses in the tumor cells
[14, 15]. However, little is known about SFV infections in
dogs. In an early study, virulent prototype SFV strain
caused neurologic signs of infection in puppies when ad-
ministered intraperitoneally and intracerebrally but was
asymptomatic upon intranasal, intradermal, or intracardial
exposure [16]. The oncolytic capacity of SFV or any other
alphavirus has not been investigated in canine cancer cells.
We hypothesized that attenuated SFV can infect and
kill canine cancer cells and that it can be safely given to
dogs intravenously. To test our hypothesis, we infected,
as a proof-of-concept, two canine osteosarcoma cell
lines (Abrams and D17) in vitro with SFV vector VA7-
EGFP and assessed virus replication and cell killing. In
addition, we performed a minimal safety study in non-
tumor bearing adult Beagles using ~2 × 105 plaque
forming units (PFU) of the unmodified parental virus
SFV A7(74) given via intravenous infusion. Our results
show, on one hand, that dog tumor cells are able to sup-
port replication of oncolytic SFV, and on the other hand,
that a limited inoculum of virus does not elicit side-
effects in healthy adult dogs. These results pave the way
for clinical translation of attenuated SFV in canine can-
cer patients.
Results
Cultured canine cells are permissive to SFV
We first tested the oncolytic capacity of attenuated SFV
in canine cancer cells by infecting two canine osteosar-
coma cell lines, Abrams and D17, at various plaque-
forming unit (PFU) to cell ratios (MOI =multiplicity of
infection) with our reporter virus VA7-EGFP. Infection
was productive in both cell lines, as seen by progressive
increase in virus-expressed fluorescent reporter protein,
concomitant with progressive cytopathic effects (Fig. 1a)
and cell loss (Fig. 1b). Oncolysis was more pronounced
in Abrams than in D17 cells at 48 h (Abrams: MOIs 0 vs
0.01, 0,1 and 1, P < 0.001 in all and D17: P = 0.0053,
0.008 and 0007, respectively) (Fig. 1b,c). The rate of
oncolysis was comparable to sensitive human glioma
cells [10].
Intravenous administration of SFV displayed good safety
in adult Beagles
Two adult female laboratory Beagles were administered by
intravenous infusion approximately 2 × 105 PFU of non-
recombinant parental SFV A7(74), accounting for a degree
of virus inactivation in saline during animal preparation.
We kept the injection dose relatively low to assess potential
self-amplifying viremia, which is a hallmark of alphavirus
infection in susceptible mammalian hosts [17, 18]. Neither
dog showed any clinical signs of infection in any time post
infusion. Total white blood cell and differential counts are
presented in Fig. 2 and clinical chemistry in Table 1. These
results revealed only a minor decrease in serum albumin
concentration in dog 2 3 weeks after virus administration,
while low blood glucose was detected in dog 1 1 week and
in dog 2 3 weeks after virus administration. Further, dog 2
had slightly low sodium concentration three weeks after
virus administration. In addition, both dogs had low serum
bilirubin, protein, and cholesterol already at baseline com-
pared to the reference values, which remained at similar
levels during the study.
Infectious SFV was not detected in the sera, urine, or
feces of the dogs
In order to determine the sensitivity of our virus detec-
tion assay in feces, a negative baseline sample (0.1 g)
from each dog was spiked with 106 PFU and diluted in
DMEM. Virus recovery from these samples as shown by
plaque assay was 6.25 × 104 PFU/0.1 g (6.25 % recovery)
and 3.75 × 105/0.1 g PFU (37.5 % recovery) in dog 1 and
dog 2, respectively. Thus, using the lower recovery rate,
the smallest theoretical amount of feces giving at least
one plaque in the assay was 400 PFU/g. Live virus could
not be recovered from any of the analyzed serum, urine,
or fecal samples. The theoretical detection limit for li-
quid samples was 25 PFU/ml.
SFV infusion induced high levels of NAbs
Levels of neutralizing antibodies (NAbs) in serum samples
collected before virus injection and 9 and 21 days post infu-
sion were determined by plaque inhibition assay.
NAbs were not present at baseline, while NAb titers of
1250 on day 9 and 250 on day 21, respectively, could be
detected in both dogs. Our results thus indicate that
both dogs had obtained virus and mounted a humoral
immune response in the absence of detectable viremia.
SFV administration did not induce histopathological
changes
Necropsy and histopathology showed no specific find-
ings associated with the virus administration. No virus
antigen was detected in any of the organs analyzed.
Discussion
Oncolytic viruses carry great potential as broadly active
cancer therapeutics, as they simultaneously interfere
with multiple cell survival signaling pathways and trigger
inflammatory responses, which, in turn, may expose the
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tumors to the immune system. In the present study, we
have assessed the potential of a promising oncolytic can-
didate, attenuated SFV, to target canine cancer. Like
most human and rodent cancer cell lines in culture [5],
also the two tested dog tumor cell lines were permissive
to the virus (Fig. 1). Thus, SFV harbors intrinsic killing
capacity against dog tumor cells, a prerequisite for the
virus as a potential therapeutic for canine cancer.
While using a broader panel of dog tumor cells may
reveal relative degrees of permissiveness to SFV, we have
noticed that tumor sensitivity to lysis in vitro may not
correlate to therapy efficacy in vivo, rendering extensive
in vitro killing assays unwarranted [15, 19, 20]. Stromal
cells and physical barriers contribute to restriction of
virus spread in vivo, as infection triggers local inflamma-
tory responses principally mediated by type I IFN to
which the tumor cells may respond [21]. Paracrine cyto-
kine signaling also serves to control alphavirus infection
before further innate and adaptive immune responses
have time to take place. However, in normal amplifying
hosts, this signaling is sufficiently low to allow for sys-
temic replication [22–24]. Indeed, the attenuated A7(74)
used in our study typically induces in susceptible mam-
malian hosts an asymptomatic viremia of up to 108
PFU/ml, lasting 1–4 days [17, 22, 25–27]. However, we
did not detect any infectious virus in the blood, urine, or
feces in the experimental dogs at any time post infusion,
suggesting that healthy dog tissues are poorly permissive to
SFV, resulting in absence of viremia and viral shedding. In
theory, the used input dose of approximately 2 × 105 PFU
could have been too low to give rise to detectable viremia.
While we cannot completely exclude this possibility, we do
not believe it to be the case as very few viral particles are
required for productive infection in susceptible host. De-
pending on the route of inoculation (and to some extent
animal species), as little as 3–8 PFU constitute the 50 %
protective dose for attenuated SFV strains against lethal
SFV strain challenge, with productive replication and 100 %
protection reached with 20 PFU administered peripherally
[17, 22, 28]. Of note, rabbits, which are significantly larger
than mice, still required only 20 PFU to receive 50 % pro-
tection against lethal challenge, and while protection
against lethal virus challenge may occur in the absence of
viremia, it does require productive replication, as defective
or inactivated SFV elicits poor protective immune re-
sponses compared to live virus [29, 30]. Therefore, the
avirulent SFV strain infection in normal animals is
self-regulating and may present as viremia and/or neu-
tralizing anti-SFV antibody response.
The neutralizing antibody response observed in both
dogs in the present study indicated productive infection
by the attenuated SFV, although no infectious virus was
recovered from any blood samples or from the secre-
tions. This is in line with the results from a recent study
in healthy dogs injected with vesicular stomatitis virus,
where infectious virus could not be detected in blood at
any time post injection, but still all dogs developed anti-
viral antibodies from day 5 onward [31]. In a study with
oncolytic adenovirus injected intravenously in healthy
dogs infectious virus was not measured, but neutralizing
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Fig. 1 VA7-EGFP infects and kills the canine osteosarcoma cell lines Abrams and D17. Twenty-five thousand cells were plated on 48-well plate and infected
next day with multiplicity of infection (MOI) 0.01, 0.1, or 1. The experiment was carried out as three replicates with identical results (one replica per sample
type presented). a Infection with attenuated SFV vector VA7-EGFP was productive in both Abrams and D17 cells, as demonstrated by progressive increase
in virus-expressed green fluorescent protein over time (lower panels, MOI 0.1), concomitant with virus-induced cytopathic effects seen in the corresponding
phase contrast micrographs (upper panels). b Infection resulted in cell loss, shown by crystal violet staining at 48 h post infection (p.i.), where absence of
staining indicates cell loss. c Quantification of acid-solubilized crystal violet from experimental wells in (b) demonstrated that oncolysis by SFV was virus
dose-dependent, and that Abrams cells displayed slightly greater susceptibility to oncolysis with all MOIs tested. One asterisk represents P= 0.0053 and two
P≤ 0.0008, respectively. Values are shown in means and error bars indicate standard deviation
Autio et al. BMC Veterinary Research  (2015) 11:170 Page 3 of 9
Table 1 Serum clinical chemistry of the Beagles receiving Semliki Forest virus
Dog 1 Dog 2
Day 0 7 14 21 0 7 14 21 Reference value
ALP 106 103 101 96 103 111 111 107 33–215 U/l
ALAT 34 41 37 34 26 29 31 33 18–77 U/l
Albumin 30.6 34.9 32.8 29.9 26.2 27.3 27.4 26.3 30–41 g/l
Bilirubin 1.3 1.3 1.6 1.9 1.1 0.6 1.3 1.1 2.5–8.5 μmol/l
Phosphate 1.34 1.46 1.29 1.44 1.51 1.76 1.27 1.28 0.93–2.25 mmol/l
Glucose 5.2 3.5 4.2 2.9 5.7 4.7 5.1 3.6 4.0–6.4 mmol/l
Potassium 4.8 4.6 4.6 4.5 5 4.9 5.1 5.3 4.2–5.4 mmol/l
Sodium 148 148 148 147 147 148 149 144 147–157 mmol/l
Calcium 2.58 2.88 2.7 2.65 2.58 2.56 2.54 2.51 2.3–3.0 mmol/l
Cholesterol 3 3.8 3.3 3.1 2.5 2.6 2.4 2.1 3.7–9.8 mmol/l
Creatinine 58 69 67 58 57 62 61 55 57–116 μmol/l
Protein 49 57 54 48 45 50 49 45 58–77 g/l
Urea 4.3 5.2 5.3 8.9 6.1 4.6 4.4 7.4 2.4–8.8 mmol/l
Bold numbers refer to values that are outside the reference range
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Fig. 2 White blood cell count over time in dog 1 (a) and in dog 2 (b) after Semliki Forest virus infusion. SFV did not cause significant changes in
any blood cell counts over the duration of the study. Leuk, leukocytes; Neutr, neutrophils; Mono, monocytes; Lym, lymphocytes; Eos, eosinophils;
Bas, basophils
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antibodies increased already 4 days after virus adminis-
tration [32]. So far, the only dog study in which infec-
tious virus has been recovered after injection was with
vaccinia virus, but the virus was recovered only from
blood samples taken immediately after the intravenous
administration [33]. Also in that study, neutralizing anti-
body responses were demonstrated 2 weeks after virus
injection. The relevance of the anti-viral antibodies in
oncolytic virotherapy remains incompletely understood,
as their presence did not seem to correlate with treat-
ment efficacy for example in patients receiving oncolytic
vaccinia- [34, 35] or adenovirus [36–38]. However, the
apparent difficulty to detect infectious viruses in dogs
suggests rapid absorption of a number of different onco-
lytic viruses. This may have implications for intravenous
delivery or systemic spread of oncolytic viruses in treat-
ment of canine cancer patients. On the other hand, poor
permissiveness of normal dog tissues to oncolytic viruses
may be beneficial from a safety perspective.
Oncolytic adenovirus has so far showed excellent
safety in tumor-bearing [39] and healthy dogs [32], likely
owing in part to its restricted species tropism. Oncolytic
vaccinia virus was reported to induce mild fever and an
apparent epileptiformic seizure in healthy Beagles [33].
Several mild to moderate adverse events and one severe
liver toxicity resulting in euthanasia were reported in
healthy Beagle dogs receiving high-dose oncolytic ves-
icular stomatitis virus [31]. Unlike vesicular stomatitis
virus, attenuated SFV can be safely injected intracranially
in adult animals, where virus replication remains con-
fined to mainly perivascular foci [11, 24, 40]. CD8+ T-
cell-mediated elimination of the virus may in certain
mouse strains be associated with demyelination [41–43],
but such effects are transient and without apparent clin-
ical symptoms [44]. Notably, we did not see any patho-
logical changes or cellular infiltrates in the dog brains
post-mortem.
In light of the poor capacity of SFV to replicate in dogs
upon intravenous injection, clinical application of the virus
in canine cancer patients would most likely entail intratu-
moral virus injections ensuring successful delivery of the
virus into the tumor mass. This route has occasionally
proven to be therapeutically superior over systemic admin-
istration even in susceptible hosts [11, 13]. Theoretically,
SFV could amplify in tumors of canine cancer patients, dis-
seminate into the blood and then be spread during the
viremia by Aedes mosquitos endemic in the tropical areas
[45]. Hence, viremia and shedding parameters should be
established separately for canine cancer patients in the
future.
Conclusions
We report here the first proof-of-principle data for Sem-
liki Forest virus as a candidate oncolytic agent in dogs.
As our results demonstrate, live attenuated SFV VA7-
EGFP was able to replicate and kill canine osteosarcoma
cells in vitro, and parental A7(74) strain was safe causing
no visible symptoms or distress in the laboratory Bea-
gles. No virus could be detected in any of the organs,
blood or secretions analyzed. Our findings support pro-
ceeding with SFV mediated oncolytic virotherapy to first
stage clinical studies in canine cancer patients.
Methods
Virus and cell lines
Generation of the plaque-purified replication compe-
tent, attenuated A7(74) strain of SFV, kindly donated
by Dr. R. E. Shope at the Yale Arbovirus Research Unit
(Yale School of Medicine, CT, USA), has been described
previously [17]. Generation of replication competent,
attenuated VA7-EGFP expressing enhanced green fluor-
escent protein used in the in vitro studies has been also
described earlier [8]. Viruses were amplified in BHK-21
baby hamster kidney cells (obtained from ATCC; Manassas,
VA, USA) grown in high glucose (4.5 g/l) Dulbecco’s modi-
fied Eagles’s medium (DMEM; D6046, Sigma-Aldrich, St
Louis, MO, USA) supplemented with 5 % fetal bovine
serum (FCS), 2 mM L-glutamine, penicillin-streptomycin
and 20 mM HEPES. The virus containing supernatant was
collected 24 h post infection (p.i)., cell debris spinned down,
and the supernatant sterile-filtered using 0.2 μm filter be-
fore freezing the virus in -70 °C in work aliquots.
Two canine osteosarcoma cell lines, Abrams (kindly do-
nated by Dr. D. Vail, University of Wisconsin-Madison,
USA,) and D17 (kindly donated by Dr. R. Alemany, Catalan
Institute of Oncology, Barcelona, Spain) [46], were tested
mycoplasma- free and grown in DMEM with 1 g/l glucose
(D6046, Sigma Aldrich) supplemented with 1 % L-glutam-
ine and 1 % penicillin-streptomycin. The culture medium
was supplemented with 5 % FBS for Abrams and 10 % FBS
for D17. Vero cells (obtained from ATCC) were grown in
DMEM with 1 g/l glucose (D6046, Sigma Aldrich) supple-
mented with 25 mM HEPES, 1 % L-glutamine, 5 % FBS,
and 1 % penicillin-streptomycin.
Infection of canine cell lines
Abrams and D17 cells were plated on 48–well plates at a
density of 25,000 cells/well. The next day, the cells were
infected with VA7-EGFP at MOI of 0.01, 0.1, and 1.
Growth medium was used as sham treatment and all sam-
ples were prepared as triplicate with identical results.
Virus infection was monitored by fluorescence micros-
copy and cytopathic effect was evaluated by phase con-
trast microscopy (Zeiss Axio Observer Z1 microscope,
Zeiss, Oberkochen, Germany) 24 and 48 h p.i. Finally,
crystal violet staining was performed to reveal cytopathic
effect at the final time point of 48 h p.i. and stained plates
were imaged with digital camera. For quantification of cell
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viability, crystal violet from stained wells was dissolved in
250 μl 10 % acetic acid for 20 min in room temperature in
a shaker. Samples from dissolved dye were transferred to
96-well plate and absorbance was measured at 595 nm
wavelength with plate reader (VICTOR2, PerkinElmer,
Waltham, MA, USA).
Dogs
Two healthy adult female HsdRcc:DOBE Beagle dogs
(Harlan Laboratories, Gannat, France) were infected with
A7(74) strain of SFV. Both dogs were 1 year old retired
breeding females. The dogs were housed together in
standard conditions, fed twice daily, and given water ad
libitum. The experiment was approved by the National
Animal Experiment Board of the Regional State Adminis-
trative Agency of Southern Finland (ESAVI/3231/
04.10.07/2013). Dog 1 weighed 6.7 kg and dog 2, 12.9 kg.
Study design
Before virus administration, an intravenous catheter
was placed into the cephalic vein and 10 ml of sterile
saline was administered to ensure vein access. As SFV
is pH-sensitive and could potentially suffer from inacti-
vation in physiological saline which lacks buffering cap-
acity, we chose to inject 1 million PFU of the virus in
order to expose the dogs to a minimally infective dose
(see Discussion). Virus was diluted in 50 ml of saline
(0.9 % Sodium Chloride Irrigation, Baxter, Norfolk, UK)
and kept on ice until given to the dogs via intravenous
infusion over 15 min (200 ml/h). The infusion line ran
through tempered water bath (37 °C) before entering
the vein. After virus administration, the virus-saline
bag and infusion line were flushed with 25 ml of saline
at the same infusion rate to ensure that the dogs
received the entire dose of virus. Altogether the infu-
sions lasted for approximately 23 min.
The dogs were monitored for adverse events according
to the Veterinary Cooperative Oncology Group - Com-
mon Terminology Criteria for Adverse Events (VCOG-
CTCAE) v1.1 [47]. Attitude, respiratory rate, heart rate,
color of mucous membranes, capillary refill time, rectal
temperature, and blood pressure were monitored before
virus administration, then 15 and 30 min, and 1, 2, 4, 8,
11, and 24 h after the initiation of virus infusion. In
addition, the dogs were monitored for swelling, itching,
and vomiting, which are the most common signs of
hypersensitivity in this species. After 24 h, attitude and
appetite were monitored twice daily, and weight, respira-
tory rate, color of mucous membranes, capillary refill
time, and rectal temperature once daily. The dogs were
euthanized 3 weeks after virus infusions, and had full
necropsy.
Sample collection
The sample collection schedule is shown in Fig. 3. Four
milliliters of blood were collected into serum tubes for
virus detection from jugular, cephalic, or saphenous vein
before and 2, 4, and 22 h and 2, 4, 7, 9, 14, and 21 days
after virus infusion. Urine (5 ml) was collected by cysto-
centesis and feces (10–15 g) were collected rectally.
Serum was separated after 20 min incubation in room
temperature by centrifuging 10 min 2400 g. It was then
frozen first at -18 °C and transferred the same day into
-80 °C until virus titer analysis. Urine and fecal samples
were frozen and stored according to the same protocol.
One milliliter blood was collected for hematology be-
fore, and 1, 2, and 4 days after virus administration and
then three times weekly. In addition, 6 ml of blood were
collected into serum tube for clinical chemistry and the
assessment of SFV antibody titers before virus infusion
and then, 9–21 days after virus administration. Serum was
separated as described earlier. Hematological parameters
were determined by an automated analyzer (ADVIA 2120i
Hematology System, Siemens Healthcare Diagnostics Inc.,
Tarrytown, NY, USA) and serum was assayed by a clinical
chemistry analyzer (Konelab 30i, ThermoFisher Scientific,
Vantaa, Finland). Urinalysis was done once a week by
dipstic (Multistix ®10 SG, Siemens Healthcare Diagnostics
Inc.) read with automated reading device (Clinitek Status,
Fig. 3 Study chart and sample collection for safety evaluation of Semliki Forest virus in two Beagle dogs. V Virus administration, Nab Neutralizing
antibodies, * Complete blood count, † Chemistry panel and urinalysis, ‡ Blood for virus detection, § Urine and feces for virus detecttion,
E Euthanasia
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Siemens Healthcare Diagnostics Inc.) Specific gravity was
determined by refractometry, and a standard volume
(0.5 ml) of urine sediment was examined under a light
microscope using 10× and 40× objectives after centrifuga-
tion (5 min 600 g). Urine protein-creatinine ratio was
measured by a clinical chemistry analyzer (Konelab 30i).
Samples for SFV antibody titer were frozen first at -18 °C
and transferred the same day into -80 °C until analysis.
Hematology, chemistry panel, and urinalysis were ana-
lyzed the day they were collected.
Virus titration
Sera obtained from the dogs were titered for SFV A7(74)
on Vero cells according to Ruotsalainen et al. [15]. Serial
dilutions of samples were prepared in cold medium.
Stock A7(74) virus was used as a positive assay control.
In order to exclude the possibility that the virus had
been inactivated during infusion procedure, we simu-
lated the conditions of the virus administration protocol
by keeping the A7(74) virus -containing sterile saline
infusion bag on ice for 3 h 25 min. This was the max-
imum time from the virus infusion preparation, per-
formed in a separate BLS2 facility, until the end of the
virus infusion. We then keept the virus-saline mixture
for 1 min in a 37 °C water bath, and finally collected and
titered the viral solution by plaque assay in Vero cells.
The protocol for virus titration from urine and feces
samples was modified from Buonacurio et al. [48]. Urine
samples were diluted 1:10 and 1:100 in DMEM with 1 g/
l glucose and virus titration was performed on Vero cells
as for the sera. Before virus titration from fecal samples
10× (w/v) of DMEM was mixed with the feces (0.1–
0.2 g), and centrifuged at 3000 g for 10 min at 4 °C. The
supernatant was sterile-filtered using 0.22 μm polyethersul-
fone membrane syringe filter (Syringe Filter, Porvair Sci-
ence, Leatherhead, UK) and diluted in growth medium 1:10
and 1:100 for titration purposes. Recovery controls were
prepared for fecal samples by adding 106 PFU of SFV
A7(74) per 0.1 g of baseline fecal samples of the two dogs
diluted in 10× (w/v) amount of medium. The virus-feces-
medium mixtures were then vortexed, sterile filtered, serial
diluted (from 10−1 to 10−6) in growth medium, and titered
as described above.
Neutralizing antibodies
NAbs were measured from the serum samples collected on
baseline, and 9 and 21 days after the virus infusion accord-
ing to Ruotsalainen et al. [19]. Briefly, titering of NAbs was
performed on Vero cells plated on 12-well plates. The
serum samples were diluted 1/2, 1/5, 1/25, 1/125, 1/625
and 1/3125 in DMEM, and the dilutions mixed 1:1
(100 μl:100 μl) with A7(74) solution containing 50 PFU of
virus. The mixture was incubated on ice for approximately
30 min before plaque titering on Vero cells seeded on 12-
well plates as duplicates. Pure medium served as a negative
control, and polyclonal rabbit anti-SFV antibody in DMEM
as a positive control. Fluorescence was monitored by fluor-
escence microscope (Zeiss Axio Observer Z1 microscope).
The neutralizing antibody titer was defined as the greatest
dilution of virus completely preventing plaque formation.
Necropsy
Necropsy and histopathological examination were per-
formed by a board-certified pathologist (MOA). Represen-
tative samples of all selected organs (Additional file 1) were
collected and fixed in 10 % buffered formalin. All samples
were dehydrated, embedded in paraffin, sectioned, and
stained with hematoxylin and eosin. In addition, tissue sam-
ples obtained from organs previously known to harbor SFV
in mice [9, 49] (brain hippocampus, cortex, corpus callo-
sum, cerebellum and pons; kidneys; liver; lymph nodes:
mandibular and mesenteric; skeletal muscle; spleen; cervical
spinal cord) were stained by polyclonal rabbit anti-SFV
antibody using Vectastain ABC kit (Vector Laboratories,
Burlingame, CA, USA) followed by hematoxylin counter-
stain. SFV envelope antigen-positive mouse brain was used
as a control. Sections were examined under microscope via
40× and 10× objectives.
Statistical analysis
Cell viability in percentages was counted from absorbance
using formula: (A595(sample) / mean A595(uninfected
sample)) × 100. The data was plotted and analyzed with
GraphPad Prism (GraphPad Software, Inc. La Jolla, CA,
USA). Statistical analysis was done using unpaired, two-
tailed t-test and P < 0.01 was considered significant.
Additional file
Additional file 1: Tissue list for histopathology collection from the
dogs receiving Semliki Forest virus (SFV). (DOCX 14 kb)
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